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Abstract
We present the case of a 52-year-old male patient with recurrence of a soft-tissue sar-
coma of the left leg treated with percutaneous laser ablation. The patient received the 
diagnosis of sarcoma for the first time in 2011; further local recurrences and a pulmonary 
metastatic spread occurred during follow-up, so the patient has been treated several 
times with chemotherapy, limb-sparing surgery and radiotherapy. In September 2017, 
a new local recurrence of sarcoma occurred, for which limb amputation was proposed 
but refused by the patient. Laser ablation with ultrasound guidance was performed, with 
complete ablation at 6 months and limb salvage.
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Introduction
Sarcomas represent a heterogeneous group of about 100 subtypes of soft-tissue and 
bone tumours of mesenchymal origin [1]. They are rare in the adult population, account-
ing for approximately 1% of all newly diagnosed malignancies annually [1–3], while they 
are more frequent in the paediatric population, accounting for 15% of all the tumours in 
this age group [3].
The first-line treatment for early stage (non-metastatic) sarcomas is surgery, which must 
be carried out as early as possible to increase healing probability [1–4]. In fact, if surgi-
cally removed, sarcomas can be cured [1].
Even after a complete remission following the primary treatment, 30%–35% of bone sar-
coma patients and about 50% of soft tissue sarcoma patients experience local or sys-
temic relapse [3, 4]. The complete removal of all tumours, irrespective of local or systemic 
recurrence, is advocated to achieve long-term survival [3].
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Nevertheless, not all patients benefit from surgical treatment and unfortunately, many patients are metastatic at the onset of the disease 
while more than 50% of patients develop metastases during the course of their disease [1, 3]. Lungs are the predominating site of metastases 
and the exclusive site in over 50% of patients at the first metastatic event [1, 3, 5]. In patients with metastatic disease, the standard treatment 
is neoadjuvant chemotherapy and radiotherapy; chemotherapy generally prolongs survival by a few months [1].
Radiotherapy aims to provide adequate local control, but its role remains controversial in ideal treatment sequence with surgery and improve-
ment in survival [2].
Percutaneous image-guided thermal ablations have been used in different clinical settings, with the aim of achieving the complete ablation 
of the tumour with reduced invasiveness in comparison with surgical resection. However, few reports have described the clinical application 
of image-guided thermal ablations in the treatment of recurrent sarcomas [1–10] and the majority of them referred to the treatment of liver, 
lung or other organs’ metastases. In particular, among the different ablative techniques, percutaneous laser ablation (PLA) seems to represent 
the ideal technique for treating small lesions in critical structures due to the very small calibre of the applicator and the extreme precision of 
the ablation area.
In the present paper, we report a case of a patient with recurrent sarcoma successfully treated with the use of PLA.
Case
A 52-year-old man received the first diagnosis of a monophasic fibrous synovial sarcoma of the left popliteal fossa in 2011, at the age of 45.
In the same year, he had the first surgical intervention, which consisted of the enucleation of a lesion on the thigh. Then, despite two subse-
quent cycles of chemotherapy (Ifosfamide and Epirubicin), the disease locally progressed, so the oncologists decided to perform preoperative 
radiotherapy and then a second, more radical surgical intervention the year later.
Until the end of 2014, the patient was stable, with no local or systemic recurrences.
He had to be treated again in 2015 and 2016 for local relapses with limb-sparing surgeries, including also a left femoro-popliteal bypass. After 
these operations, the disease distantly progressed with a pulmonary metastatic spread. Then, the patient was treated with four high-dose, neo-
adjuvant chemotherapy cycles (Ifosfamide), unfortunately without a complete response: the lung lesions decreased but did not completely dis-
appear. So, in August 2017, the patient underwent microwave ablation of the four larger lung lesions in order to achieve control of the disease.
Moreover, on 2 October 2017, control magnetic resonance imaging (MRI) of the left leg and knee showed a new local relapse consisting 
of two pathologic nodules: one of 8 mm near the scar of the lateral calf of the gastrocnemius and one of 14 mm near the scar in the soleus 
muscle. Both nodules were also visible at ultrasound (US) examination (Figure 1A and B).
Lesion surgical excision was considered not feasible due to previous therapies, and the first proposed treatment option for this recurrence 
was leg amputation, which the patient refused. Thus, together with the patient’s oncologist and radiation oncologist, the interventional 
radiologist decided to attempt treatment with PLA under US-guidance in order to avoid a major amputation.
The patient agreed and gave informed consent to the treatment.
Procedure
Before starting the procedure, 0.5 mg im of atropine and 2 mg iv of midazolam were given to the patient. Then, the patient was turned into 
the prone position. US examination, performed also with contrast material (contrast-enhanced ultrasound (CEUS)), showed both the lesions 
in the soft tissue of the posterior sector of the left leg.
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Local anaesthesia with Mepivacain diluted in physiological solution was injected at the level of the more dorsal lesion, also achieving a sepa-
ration of the lesion from the skin (Figure 2A). Under US-guidance, PLA was performed by using a laser unit (Echolaser, Elesta Srl, Florence, 
Italy). The laser source is a semiconductor diode with a wavelength of 1,064 nm, and a multi-source device enables the use of up to four 
300 μm fibres at once. A 21-gauge Chiba needle was placed in the centre of the lesion. Then, a bare-tip, 300 μm in diameter laser fibre was 
introduced through the needle. Ablation with one pull-back and a total amount of energy of 2,400 Joules was performed at a fixed power of 
3 W (Figure 2A and C).
During the procedure, the patient also underwent continuous monitoring of pulse-oximetry, electrocardiography (ECG) and blood pressure.
At the end of the procedure, a CEUS showed a good devascularisation of both the treated lesions with a good safety margin. In fact, there 
was no evidence of residual hyper-enhancing foci, suggesting complete necrosis of both nodules (Figures 3 and 4).
No complications were observed during or after treatment.
Figure 1. US examination shown in (A): The 14-mm pathologic nodule (arrow) near the scar in the soleus muscle and (B): The 8-mm pathologic nodule 
(arrow) near the scar of the lateral calf of the gastrocnemius.
Figure 2. Laser ablation. (A): Injection of local anaesthesia through a small needle (arrow) at the level of the more dorsal lesion (star). (B): A bare-tip, 300 μm 
in diameter laser fibre, is introduced through a small needle (arrow) into the lesion to be treated (star). (C): The arrows show the gas bubbles produced by the 
procedure. After another injection of local anaesthesia and hydro-dissection, the medial lesion was treated inserting two parallel 21-gauge Chiba needles and 
laser fibres. Thermal ablation was performed with one pull-back and a total energy of 3,200 Joule.
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Figure 3. Post-treatment CEUS showing large avascular area, including the 14-mm treated nodule (arrows).
Figure 4. Post-treatment CEUS showing large avascular area, including the 8-mm treated nodule (arrows).
MRI study with and without contrast-enhancement was performed within 2 months after laser ablation to evaluate the antitumour effects. 
The exam showed the complete disappearance of tumour enhancement of both treated nodules, without signs referable to the persistence 
of the disease or to the appearance of new solid nodules suspected for active disease. This was regarded as complete tumour ablation.
Two months after PLA, CEUS also confirmed the good outcomes of treatment, showing no enhancement of the treated nodules, smaller than 
before the treatment (Figure 5).
However, CEUS showed the appearance of two new suspected nodules, cranial and lateral compared to the treated ones, the major 8 mm 
long. These new nodules were confirmed at US examination 6 months after PLA while previously treated lesions were further reduced.
Discussion
The therapeutic approaches in patients with locally recurrent sarcomas have been largely debated during the last decades [6, 11]: for some 
authors, the outcome in patients with recurrent extremity soft-tissue sarcomas depends on metastatic disease [12], for others, it relies on 
the control of the primary tumour [13]. For these reasons, an aggressive approach is warranted in the treatment of local recurrence [6]. 
Local treatments include surgery and radiotherapy. Percutaneous tumour ablation techniques, especially radiofrequency ablation, have been 
attempted in few cases to achieve local control of the disease [1–3, 6]. A significant advantage of percutaneous thermal ablation over surgery 
and radiation includes the repeatability of ablation, as it might be repeated several times in case of recurrence [7]. Moreover, compared with 
surgery, ablation offers the potential of decreased recovery time, a less invasive procedure, and is often performed in patients deemed not 
medically fit for surgery [7].
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Figure 5. Two months after PLA, the 14-mm nodule appeared smaller (8 × 4 mm) than before the treatment (arrow).
Particularly, as in our case, image-guided thermal ablation offers the possibility to postpone or avoid limb amputation, with a significant 
advantage for the patients’ quality of life.
To the best of our knowledge, only a few reports have described image-guided ablations in controlling recurrent sarcomas [1–10] and the 
majority of them referred to the treatment of liver, lung or other organs’ metastases.
In 2014, Yamakado et al [3] published a retrospective study about the clinical utility of radiofrequency ablation (RFA) in 52 inoperable patients 
(two of whom were children) with recurrent bone and soft-tissue sarcomas. In this study, they showed that RFA was a useful and safe therapeutic 
option in these patients [3].
In 2015, Belfiore et al [6] also published a case report about the use of RFA under computed-tomography (CT) guidance to treat a 13 cm 
recurrent malignant fibrous histiocytoma of the right thigh in an 83-year-old female patient. After ablation, a marked shrinkage of the tumour 
was obtained. Further local recurrences occurred during follow-up and were safely treated by RFA. At the 6-year follow-up, the patient was 
still alive and presented a local control of disease, without the metastatic spread of the tumour [6]. Belfiore et al [6] reported RFA to be 
safe, effective and repeatable for soft-tissue sarcoma recurrences, allowing long-term local control of the disease. Even if from these small 
experiences it is not possible to draw definitive conclusions regarding the role of thermal ablations in soft tissue sarcomas, it seems possible 
to consider thermal ablations among the toolbox of therapeutic options to be taken into consideration when disease control is the goal of 
treatment and invasiveness needs to be kept at a minimum.
Jones et al [4] aimed to evaluate the efficacy and safety of RFA for both lung and liver metastases in a series of sarcoma patients, demon-
strating that it was feasible, effective and well tolerated if the goal of therapy is local disease control. The role of interventional radiology in 
treating metastatic soft tissue sarcomas is also mentioned in the works of Gronchi et al [5] and Olivier et al [1]. Moreover, Jones et al [4] and 
Olivier et al [1] found RFA most effective to treat lesions ≤ 35 mm in inoperable patients.
We chose to treat our patient using PLA because of the number and the dimensions of the lesions. In fact, PLA has been proposed as the 
ablation technique of choice in patients with multiple and small tumours or for cases with a high-risk location of the lesion to be treated, such 
as lesions in the neck or renal tumour at high bleeding risk [14–17]. Moreover, the diameter of PLA needles is smaller than RFA electrodes 
and microwave ablation antennas, making PLA safer and more suitable to ablate lesions with at-risk location and/or difficult to be reached 
[17–19].
Moreover, both lesions were visible at US examinations, so we decided to treat them under US guidance; as mentioned above, other authors 
opted for an ablation treatment under CT guidance [3, 6].
In case of poor visibility at US, the use of CEUS has been reported to be extremely helpful to enhance the conspicuity of a lesion in order to 
better depict it and to enhance the accuracy of image-guided targeting [20].
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Moreover, immediate post-procedural CEUS is strongly recommended to assess the completeness of the ablation treatment and to guide the 
immediate re-treatment in case of residual viable tissue [21–23].
Another option that can help interventional radiologists in cases of lesions being invisible at US and not completely depictable with CEUS 
is the use of virtual navigations systems and fusion imaging, which has been reported to be a safe, feasible and effective strategy [24–26]. 
Finally, hydrodissection can be used to achieve a safe distance between the target lesion and surrounding critical structures, thus making it 
possible to also perform ablation in cases with difficult location [14, 24]. In the presented case, we used hydrodissection to achieve a safe 
distance between the lesion and the superficial skin and deep structures, such as surgical bypass. This allowed us to perform a complete 
ablation without damaging surrounding critical structures.
Conclusion
In conclusion, from our very preliminary experience, PLA seems to represent a feasible, tolerable and effective technique for the local control 
of recurrent sarcomas. Further studies on larger series are needed to confirm these preliminary results. PLA can be considered to be within 
the therapeutic toolbox for patients with sarcoma when the principal aim is to achieve local disease control by minimising treatment invasive-
ness.
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